Photo from Matthias Ocker/X
Aug 31, 2024, 18:32
Matthias Ocker: Novel small molecule MCL-1 inhibitor in vivo clearance and robust efficacy in solid and hematological tumor models
Matthias Ocker, Head of Experimental Medicine at Tacalyx GmbH, shared on X:
“I’m excited to share our recent publication on a novel small molecule MCL-1 inhibitor now out in Nature Cancer. Thanks to an outstanding team to accomplish this.”
Authors: Ulrike Rauh, Guo Wei, Michael Serrano-Wu, Georgios Kosmidis, Stefan Kaulfuss, Franziska Siegel, Kai Thede, James McFarland, Christopher T. Lemke, Nicolas Werbeck, Katrin Nowak-Reppel, Sabine Pilari, Stephan Menz, Matthias Ocker, Weiqun Zhang, Kyle Davis, Guillaume Poncet-Montange, Jennifer Roth, Douglas Daniels, Virendar K. Kaushik, Brian Hubbard, Karl Ziegelbauer, Todd R. Golub
Source: Matthias Ocker/X
Brian Hubbard
cancer
Christopher T. Lemke
Douglas Daniels
Franziska Siegel
Georgios Kosmidis
Guillaume Poncet-Montange
Guo Wei
James McFarland
Jennifer Roth
Kai Thede
Karl Ziegelbauer
Katrin Nowak-Reppel
Kyle Davis
Matthias Ocker
Michael Serrano-Wu
Nature Cancer
Nicolas Werbeck
OncoDaily
Oncology
Sabine Pilari
solid and hematological tumors
Stefan Kaulfuss
Stephan Menz
Todd R Golub
Ulrike Rauh
Virendar K. Kaushik
Weiqun Zhang
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 15, 2024, 21:37
Nov 15, 2024, 21:26
Nov 15, 2024, 21:09
Nov 15, 2024, 21:05
Nov 15, 2024, 21:03
Nov 15, 2024, 21:02
Nov 15, 2024, 20:28
Nov 15, 2024, 19:31
Nov 15, 2024, 17:47
Nov 15, 2024, 17:45